Faster global financial news!
Biopharmaceuticals
-
Chinese Biopharma Stocks Rise as US Considers Allowing Most Drug Licensing Deals with Chinese Pharma Companies to Continue
On Monday, the Hang Seng Biotech Index rose over 5%, with Innovent Biologics up 6%, Akeso up 8%, CSPC Pharmaceutical Group up over 6%, Hutchmed up 3%, and Sino Biopharmaceutical up 8%. This follows re
-
Experts at Nordic Life Science Days suggest China's biopharma rise may be plateauing due to oversupply and rising prices
A panel of pharma representatives and analysts at the 2026 Nordic Life Science Days meeting in Stockholm noted that while licensing deals between US and Chinese biopharma companies hit record highs in
-
JonesTrading analysts initiated coverage on biopharmaceutical company Adlai Nortye (ANL) with a "Buy" rating and a $22 price target, projecting a 46.5% upside over the next year.
JonesTrading analyst Boris Peaker initiated coverage of biopharmaceutical company Adlai Nortye (ANL) with a "Buy" rating and a $22 price target, projecting a 46.5% upside over one year. Wall Street's
-
Seaport Therapeutics (SPTX) is attracting interest from large pharmaceutical companies after its IPO, with its lead candidate drug GlyphAllo expected to announce Phase 2b topline data in the first half of 2027.
Analysis indicates that biopharmaceutical company Seaport Therapeutics (SPTX) has attracted attention from major pharmaceutical companies such as Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ)
-
Chinese Biopharma Stocks Rise as US Considers Allowing Most Drug Licensing Deals with Chinese Pharma Companies to Continue
On Monday, the Hang Seng Biotech Index rose over 5%, with Innovent Biologics up 6%, Akeso up 8%, CSPC Pharmaceutical Group up over 6%, Hutchmed up 3%, and Sino Biopharmaceutical up 8%. This follows re
-
Experts at Nordic Life Science Days suggest China's biopharma rise may be plateauing due to oversupply and rising prices
A panel of pharma representatives and analysts at the 2026 Nordic Life Science Days meeting in Stockholm noted that while licensing deals between US and Chinese biopharma companies hit record highs in
-
JonesTrading analysts initiated coverage on biopharmaceutical company Adlai Nortye (ANL) with a "Buy" rating and a $22 price target, projecting a 46.5% upside over the next year.
JonesTrading analyst Boris Peaker initiated coverage of biopharmaceutical company Adlai Nortye (ANL) with a "Buy" rating and a $22 price target, projecting a 46.5% upside over one year. Wall Street's
-
Seaport Therapeutics (SPTX) is attracting interest from large pharmaceutical companies after its IPO, with its lead candidate drug GlyphAllo expected to announce Phase 2b topline data in the first half of 2027.
Analysis indicates that biopharmaceutical company Seaport Therapeutics (SPTX) has attracted attention from major pharmaceutical companies such as Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ)
- No data
Biopharmaceuticals
24H Trending
-
1
Regulatory Landscape and Exchange Policies for Virtual Currencies in Mainland China
-
2
Cerebras's pre-market stock rose 6% after OpenAI CEO Altman called Cerebras a "close partner."
-
3
Bitcoin (BTC): Latest Updates and Market Analysis of Digital Gold
-
4
The Deep Integration and Development of USDC with Crypto Lending Platforms
-
5
Musk reposted a tweet stating that Starlink can stream 5 college football games simultaneously on commercial flights.
-
6
Cryptocurrency Information Platforms and Software Download Guide: Secure Access to Industry News and Trading Tools
-
7
Ethereum: Market Impact, Technological Advancements, and Future Outlook
-
8
Multiple U.S. states will vote on wealth taxes in November, with California potentially imposing a 5% net worth tax on billionaires.
-
9
STEEM Coin Analysis: The Current Status and Development Challenges of a Decentralized Social Blockchain
-
10
Litecoin's price has recently surged: Can ETF applications and halving expectations sustain its rally?
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
